SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Apthera, Inc. announced today the positive completion of an End of Phase II meeting held on August 29, 2007 with the U.S. Food and Drug Administration (FDA) regarding the Company’s breast cancer therapy, NeuVax. Based on the meeting with the FDA, Apthera will submit a finalized clinical protocol to the FDA under a Special Protocol Assessment (SPA) and expects to start a Phase II/III registration trial in the first half of 2008.
